Reimbursement

Billing Information

Beginning January 1, 2010, please use the following Feraheme-specific Q-codes when billing for Feraheme in your dialysis centers, physician offices, and hospital outpatient departments:

• These codes may only be used for Feraheme administered on or after January 1, 2010

AMAG Assist™ Services

Physician Reimbursement Support

In our ongoing commitment to providers and patients, AMAG Pharmaceuticals, Inc. has established AMAG Assist. This program offers comprehensive reimbursement support services by providing the following assistance:

• Insurance verifications
• Coding and billing
  • Coding Sample Claim Forms
  • Hospital Outpatient Coding Reference
  • Physician Office Coding Reference
• Claims tracking and appeals

Patient Assistance Program

If a patient is uninsured or under-insured and no other source of drug coverage can be identified, patients may be eligible to participate in the Feraheme Patient Assistance Program. For qualified patients, free product is delivered to the patient‘s healthcare provider. When applying to the Feraheme Patient Assistance Program, you can expect the following steps:

• Enrollment process
• Enrollment assessment
• Delivery coordination

For reimbursement assistance, please contact:

AMAG Assist
(877) 411-2510, Option 2
Monday to Friday, 9:00 AM to 6:00 PM ET

Read the full guide to AMAG Assist Services.

In addition to understanding the process of reimbursement, it may help to review the Feraheme Formulary Kit.

Important Safety Information

Indication and contraindications

Feraheme is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. Feraheme is contraindicated in patients with evidence of iron overload, known hypersensitivity to Feraheme or any of its components, and patients with anemia not caused by iron deficiency.

Warnings and precautions

In clinical studies, serious hypersensitivity reactions were reported in 0.2% (3/1,726) of subjects receiving Feraheme. Other adverse reactions potentially associated with hypersensitivity (e.g., pruritus, rash, urticaria or wheezing) were reported in 3.7% (63/1,726) of subjects. Patients should be observed for signs and symptoms of hypersensitivity for at least 30 minutes following Feraheme injection and the drug should only be administered when personnel and therapies are readily available for the treatment of hypersensitivity reactions. 1.9% (33/1,726) of Feraheme-treated subjects experienced hypotension. Please monitor for signs and symptoms of hypotension following each Feraheme injection. Excessive therapy with parenteral iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Patients should be regularly monitored for hematologic response during parenteral iron therapy, noting that lab assays may overestimate serum iron and transferrin bound iron values in the 24 hours following administration of Feraheme. As a superparamagnetic iron oxide, Feraheme may transiently affect magnetic resonance diagnostic imaging studies for up to 3 months following the last Feraheme dose. Feraheme will not affect X-ray, CT, PET, SPECT, ultrasound, or nuclear imaging.

Adverse reactions

In clinical trials, the most commonly occurring adverse reactions in Feraheme treated patients versus oral iron treated patients reported in ≥2% of chronic kidney disease patients were diarrhea (4.0% vs. 8.2%), nausea (3.1% vs. 7.5%), dizziness (2.6% vs. 1.8%), hypotension (2.5% vs. 0.4%), constipation (2.1% vs. 5.7%) and peripheral edema (2.0% vs. 3.2%). In clinical trials, adverse reactions leading to treatment discontinuation and occurring in 2 or more Feraheme-treated patients included hypotension, infusion site swelling, increased serum ferritin level, chest pain, diarrhea, dizziness, ecchymosis, pruritus, chronic renal failure, and urticaria.

Please see full Prescribing Information for Feraheme.